Sirtris Pharmaceuticals Named as One of the ''Fierce 15'' Biotech Companies of 2007
June 07 2007 - 8:00AM
Business Wire
Sirtris Pharmaceuticals (NASDAQ: SIRT), a biopharmaceutical company
focused on discovering and developing small molecule drugs to treat
diseases of aging such as Type 2 Diabetes, announced today that it
has been named to the annual FierceBiotech �Fierce 15� list. The
complete list of �Fierce 15� companies is available in today�s
issue of FierceBiotech and on the FierceBiotech Web site at
www.fiercebiotech.com. About Sirtris Pharmaceuticals Sirtris
Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes that control the aging process. The company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 concerning Sirtris
Pharmaceuticals, its product candidates, and those candidates'
clinical potential. These forward-looking statements about future
expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company�s product candidates will be
safe or effective, or receive regulatory approval, the Company's
potential inability to initiate and complete preclinical studies
and clinical trials for its product candidates, the fact that none
of the Company's product candidates has received regulatory
approvals, the potential inability of the�Company to gain market
acceptance of the Company's product candidates, and those other
risks factors�that can be found in the�Company's filings with the
Securities and Exchange Commission. Actual results may differ
materially from those Sirtris Pharmaceuticals contemplated by these
forward-looking statements. Sirtris Pharmaceuticals does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024